Peginterferon 2a for the treatment of HIV infection

David M. Asmuth, Netanya S. Utay, Richard B. Pollard

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Introduction: Novel approaches are urgently needed to achieve the next level of control of HIV infection beyond antiretroviral medications that will lead to the ultimate goal of curing HIV infection. Exploiting the innate immune system control of HIV is one possible component of that strategy with pegylated interferon representing a well-characterized agent that is being applied to this effort.Areas covered: In this review, the authors summarize the history of interferon treatment in the setting of HIV infection with a focus on clinical trials that examined the downstream effects on innate immune responses. More recently, clinical trials that administered pegylated interferon 2a have demonstrated which interferon-stimulated genes are associated with its antiviral effects and which of these host-restriction factors may play a role in limiting the magnitude of the HIV reservoir.Expert opinion: The potential to exploit interferon as part of a cure strategy is provocative. Whether key interferon-induced antiviral factors can be upregulated sufficiently to affect the reservoir is unknown. Additional research employing pegylated interferon 2a is needed to identify which innate immune pathways are candidate targets for novel biological therapies for the potential cure of HIV infection.

Original languageEnglish (US)
Pages (from-to)249-257
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number2
StatePublished - Feb 1 2016
Externally publishedYes


  • HIV
  • HIV reservoir
  • Interferon alpha
  • humans
  • innate immune system
  • interferon stimulated genes
  • review

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Peginterferon 2a for the treatment of HIV infection'. Together they form a unique fingerprint.

Cite this